v3.26.1
Operating Segments - Segment Revenues and Profit (Loss) (Details)
12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment reporting    
Number of operating segments | segment 2  
Number of reportable segments | segment 2  
Revenues   $ 119,371
Cost of revenues   (119,371)
Research and development $ 7,485,813 5,223,589
General and administrative 4,359,663 4,215,908
Adjusted loss from operations (11,845,476) (9,439,497)
Share-based compensation 587,583 329,815
Loss from operations (11,845,476) (9,439,497)
Other (expenses) income, net 258,481 763,807
Net loss before income taxes (11,586,995) (8,675,690)
Total Segments    
Segment reporting    
Revenues   119,371
Cost of revenues   (119,371)
Research and development 6,863,635 4,483,623
Adjusted loss from operations (6,863,635) (4,483,623)
Share-based compensation 204,848 131,917
Depreciation and amortization 2,257 4,070
Loss from operations (7,070,740) (4,619,610)
Other (expenses) income, net   (22,342)
Net loss before income taxes (7,070,740) (4,641,952)
Total Segments | Specialized BioTherapeutics    
Segment reporting    
Revenues   119,371
Cost of revenues   (119,371)
Research and development 6,776,867 4,233,771
Adjusted loss from operations (6,776,867) (4,233,771)
Share-based compensation 203,169 127,774
Depreciation and amortization 1,935 3,489
Loss from operations (6,981,971) (4,365,034)
Other (expenses) income, net   (22,342)
Net loss before income taxes (6,981,971) (4,387,376)
Total Segments | Public Health Solutions    
Segment reporting    
Research and development 86,768 249,852
Adjusted loss from operations (86,768) (249,852)
Share-based compensation 1,679 4,143
Depreciation and amortization 322 581
Loss from operations (88,769) (254,576)
Net loss before income taxes (88,769) (254,576)
Adjustments    
Segment reporting    
Research and development 207,105 135,987
Adjusted loss from operations (207,105) (135,987)
Share-based compensation (204,848) (131,917)
Depreciation and amortization (2,257) (4,070)
Corporate    
Segment reporting    
Research and development 415,073 603,979
General and administrative 3,975,961 4,016,266
Adjusted loss from operations (4,391,034) (4,620,245)
Share-based compensation 382,735 197,898
Depreciation and amortization 967 1,744
Loss from operations (4,774,736) (4,819,887)
Other (expenses) income, net 258,481 786,149
Net loss before income taxes (4,516,255) (4,033,738)
Adjustments.    
Segment reporting    
General and administrative 383,702 199,642
Adjusted loss from operations (383,702) (199,642)
Share-based compensation (382,735) (197,898)
Depreciation and amortization $ (967) $ (1,744)